MedPath
HSA Approval

DECONDINE SYRUP

SIN03181P

DECONDINE SYRUP

DECONDINE SYRUP

June 12, 1989

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSUNWARD PHARMACEUTICAL PRIVATE LIMITED
Licence HolderSUNWARD PHARMACEUTICAL PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R01BA52

pseudoephedrine, combinations

Manufacturer Information

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

SUNWARD PHARMACEUTICAL SDN BHD

Active Ingredients

PSEUDOEPHEDRINE HCl

30 mg/5 ml

Pseudoephedrine

TRIPROLIDINE HCl

1.25 mg/5 ml

Triprolidine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DECONDINE SYRUP - HSA Approval | MedPath